Gilead Sciences Inc

(

GILD

) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day down 0.2%. By the end of trading, Gilead Sciences Inc fell 53 cents (-1.3%) to $39.27 on average volume. Throughout the day, 10.5 million shares of Gilead Sciences Inc exchanged hands as compared to its average daily volume of 7.9 million shares. The stock ranged in price between $39.23-$40.01 after having opened the day at $39.78 as compared to the previous trading day's close of $39.80. Other company's within the Drugs industry that declined today were:

DARA Biosciences Inc

(

DARA

), down 23%,

Accelr8 Technology Corporation

(

AXK

), down 15.1%,

Marshall Edwards Inc

(

MSHL

), down 13.9%, and

K-V Pharmaceutical Company

(

KV.B

), down 10.4%.

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Gilead Sciences Inc has a market cap of $29.5 billion and is part of the

health care

sector. The company has a P/E ratio of 11.5, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are up 9.8% year to date as of the close of trading on Monday.

TheStreet Ratings rates Gilead Sciences as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and attractive valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front,

Marina Biotech Inc

(

MRNA

), up 22.9%,

Inhibitex Inc

(

INHX

), up 20.2%,

YM Biosciences Inc

(

YMI

), up 19.8%, and

Salix Pharmaceuticals

(

SLXP

), up 12.6%, were all gainers within the drugs industry with

Bristol-Myers Squibb Company

(

BMY

) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

null